



thor medical

Thor Medical invitation to capital markets update

1.11.2024 07:00:00 CET | Thor Medical ASA | Non-regulatory press releases

Oslo, November 1, 2024: Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, is pleased to invite investors and other interested parties to a capital markets update on Monday, November 25, 2024.

Thor Medical's CEO Jasper Kurth and CFO Brede Ellingsæter will present an updated investor presentation and will be accompanied by Emanuele Ostuni, CEO of ARTBIO.

Keynote speaker for Thor Medical's Capital Markets Update is Professor Jane Sosabowski, BSc (Hons), MSc, PhD from the Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London. Professor Sosabowski will provide a perspective on treatment with upcoming targeted alpha therapies using isotopes that Thor Medical produces.

As announced on 29 October, Thor Medical has signed a 5-year master supply agreement for Thorium-228 with ARTBIO. The agreement marks a significant step towards a positive investment decision for Thor Medical's planned commercial production plant, targeted in Q1 2025.

The event will be held at Carnegie's premises in Stockholm, Sweden and a live webcast will be available for those who cannot attend in person.

Location: Regeringsgatan 56, 111 56 Stockholm

Date & Time: 25 November 2024, 13:00-15:00 CET

Registration for physical or digital attendance to the capital markets update can be done through the following link:

<https://tinyurl.com/2jx2hxzp>

It will be possible to ask questions both from the audience and via webcast during the presentations.

For inquiries regarding one-on-one meetings or other event-related questions, kindly send an email to

ellen.mioen@carnegie.se

Contacts

- Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.no

About Thor Medical ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no.

Attachments

- [Download announcement as PDF.pdf](#)